Researchers presented new findings Saturday at a breast-cancer symposium here suggesting that the risks associated with anthracyclines, a class of chemotherapy drugs widely used to treat the disease, outweighed their benefits in some patients.The findings renewed a debate over whether anthracyclines, which have been around since the 1960s, should remain the standard of care in treating breast cancer, or whether newer drugs should be used more frequently instead.
More...
A former senior adviser at the National Institute of Allergy and Infectious Diseases is facing charges...
When Bug got home from school one winter afternoon in late 2024, his mother was on...
A Pennsylvania court on Monday said that the state’s constitution guarantees a right to abortion while...
Donald Trump has selected Erica Schwartz to lead the Centers for Disease Control and Prevention (CDC),...
